Although the standard tricyclic antidepressants (TCAs) are generally e
ffective in the treatment of depression, they can cause several troubl
esome adverse effects. Chief among these are their anticholinergic act
ions, which range from annoying dryness of the mouth and constipation
to potentially dangerous urinary retention and confusion or delirium i
n the ill and elderly. Cardiovascular effects of TCAs include orthosta
tic hypotension, tachycardia and cardiac conduction slowing. Many TCAs
are sedating and promote weight gain. Also problematic is the potenti
al lethality of TCAs in overdose. The continual introduction of a host
of new antidepressants over the past 15 years has provided an opportu
nity to improve the benefit-risk ratio for many patients by reducing m
edication-related toxicity. Selective serotonin reuptake inhibitors (S
SRIs) and amfebutamone (bupropion), among others, are examples of effe
ctive antidepressants free of tricyclic-like anticholinergic, cardiova
scular, sedating and appetite/weight-increasing effects. However, the
new-generation drugs also present adverse effects of their own, includ
ing gastrointestinal distress, agitation and drug-drug interactions in
the case of the SSRIs, and the risk of seizures or psychosis in amfeb
utamone recipients. Monoamine oxidase (MAO) inhibitors have also been
refined; reversible inhibitors of MAO-type A afford protection against
the usually feared hypertensive reaction to indirect sympathomimetic
substances. The availability of new-generation antidepressants thus in
creases the likelihood of clinical response with a reduction in unwant
ed toxicity.